Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Global Genitourinary Drugs Market 2011-2015 Report Reveals That One of the Major Challenges Is the Increase in the Patent Expiries of the Best-Selling Drugs in the Market

December 3, 2013

DUBLIN, December 3, 2013 /PRNewswire/ –

Research and Markets ( http://www.researchandmarkets.com/research/67g6vc/global)
has announced the addition of the “Global Genitourinary Drugs Market 2011-2015″
[http://www.researchandmarkets.com/research/67g6vc/global ] report to their offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

TechNavio’s analysts forecast the Global Genitourinary Drugs market to grow at a CAGR
of 3.05 percent over the period 2011-2015. One of the key factors contributing to this
market growth is the entry of novel biological drugs. The Global Genitourinary Drugs
market has also been witnessing a paradigm shift toward biological drugs. However, lack of
adherence to medication could pose a challenge to the growth of this market.

The key vendors dominating this space are Abbott Laboratories, Astellas Pharma Inc.,
Bayer AG, Eli Lilly and Co., GlaxoSmithKline plc, Merck and Co. Inc., and Pfizer Inc.

Other vendors mentioned in the report are Agile Therapeutics Inc., Allergan Inc.,
Antares Pharma Inc., Boehringer Ingelheim GmbH, Dong-A Pharmaceutical Co. Ltd., Detrol LA,
Ferring Holding S.A., Kissei Pharmaceutical Co. Ltd., Merck Serono S.A., Novartis
International AG, Novo Nordisk A/S, Nymox Pharmaceutical Corp., PregLem S.A., Recordati
S.p.A., Rottapharm S.p.A., Teva Pharmaceutical Industries Ltd., VIVUS Inc., Warner
Chilcott plc, and Watson Pharmaceuticals Inc.

Commenting on the report, an analyst from TechNavio’s Healthcare team said: “Patients
suffering from infections and disorders related to genitourinary systems are using
steroids and immunosuppressants. However, these medications cause serious side effects
because they are chemically synthesized. Hence, patients are turning to biological drugs
that not only cause fewer side effects, but are also more effective in the treatment of
genitourinary infection. Moreover, there has been an increase in the number of biological
drugs entering the Global Genitourinary Drugs market.”

According to the report, one of the major growth factors driving the Global
Genitourinary [http://www.researchandmarkets.com/research/67g6vc/global ] Drugs market is
the entry of novel drugs such as Cialis which are more effective than the drugs used in
multiple-drug therapies. These novel drugs provide cost-effective treatment for
genitourinary infection.

For more information visit

http://www.researchandmarkets.com/research/67g6vc/global

        Research and Markets
        Laura Wood, Senior Manager.
        press@researchandmarkets.com
        U.S. Fax: +1-646-607-1907
        Fax (outside U.S.): +353-1-481-1716
        Sector: Pharmaceuticals
         [http://www.researchandmarkets.com/categories.asp?cat_id=16&campaign_id=67g6vc ]


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire